dalteparin has been researched along with Cardiac Cancer in 2 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willens, HJ | 1 |
| Ahn, YS | 1 |
| Gallagher, AJ | 1 |
| Saad, RA | 1 |
| Horn, L | 1 |
| Mankad, PS | 1 |
2 other studies available for dalteparin and Cardiac Cancer
| Article | Year |
|---|---|
Evaluation and management of left atrial lymphoma guided by transesophageal echocardiography.
Topics: Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Echoca | 2003 |
Management dilemma of cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Topics: Aged; Axillary Vein; Cardiopulmonary Bypass; Female; Fibrinolytic Agents; Heart Atria; Heart Neoplas | 2002 |